Theravance Biopharma (NASDAQ: TBPH) announced new positive data from several studies of VIBATIV (telavancin) confirming the product's in vitro potency ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE